Skip to content
FrontierPicks

Watching

HAE · Haemonetics Corporation

Conviction · Medium Business pivot Medtech & diagnostics

Updated ·

Against its published line

Above its line on the last close.

How to read this

The red mark is the published kill line — the price that would prove the thesis wrong. The dot is where the name closed on 30 October 2026; a dot left of the mark has closed through its line.

Distance is drawn on a square-root scale, so close calls get the room. Past 8% a row reads well clear, with a hollow dot to show the figure is off the drawn scale. Rows run tightest first.

How a pick is graded

HAEHaemonetics Corporation
$103.00
$119.65
+16.2%well clear

Kill line

A weekly close below $103, which would give back nearly all of the gain that followed CSL's 8 October 2026 rollout statement; separately, a cut to the 6–9% fiscal 2027 organic growth range or a CSL completion date later than calendar 2027.

Open pick Medium conviction, opened at $104.37. Since then +14.9% against the S&P 500's −3.8% (+18.7 pp). Kill line at open: $91.00 (weekly close); graded by at the latest.

How picks are graded →

The thesis

Haemonetics beat estimates and raised fiscal 2027 guidance on 5 November 2026, with plasma revenue up 17.7% organically before CSL Plasma contributed much. The larger CSL revenue arrives mostly in fiscal 2028, so the case now turns on whether margins recover as CSL centers convert, and the fiscal third-quarter report, expected around 4 February 2027, gives the next test.

Second-quarter revenue was $357.8 million, up 9.3% reported and 10.0% organically (excluding currency and other non-operating effects), against a $345.0 million estimate, according to the company's release and Benzinga. The company raised its organic growth range to 6–9% from 4–7%.

The report answered only part of the question the previous note set. Management declined on the 5 November 2026 call to give a CSL revenue figure, citing confidentiality and competitive reasons, which meets the condition the previous note named as breaking the case. The case continues in narrower form because guidance now includes some CSL conversions and the second-quarter contribution was, in management's word, "de minimis". The raise therefore came mostly from business already in place.

Bullish and bearish views on Haemonetics Corporation

The bull case on Haemonetics Corporation (HAE), in brief: Plasma accelerated before CSL arrived. The bear case: CSL's value remains undisclosed.

Bull case

  • Plasma accelerated before CSL arrived. Plasma revenue was $162.6 million in the quarter ended 26 September 2026, up 17.7% organically, compared with 8.2% organic growth in the first quarter, per company releases. Management said global plasma collections grew by a high single-digit percentage.
  • Guidance rose with CSL partly included. The fiscal 2027 sales range moved to $1.441–$1.481 billion from $1.401–$1.441 billion, against a $1.418 billion estimate, Benzinga reported on 5 November 2026. It includes centers converted or formally notified through 31 December and excludes further fiscal fourth-quarter conversions, management said.
  • The CSL conversion has started. Chief Executive Chris Simon said on the 5 November 2026 call that pilot work began in September and full-scale conversion in October. CSL said on 8 October 2026 that it expects to finish all of its current US centers by the end of calendar 2027.
  • The returning business has a known size. BTIG said on 8 October 2026 that US CSL revenue, excluding software, was about $155 million in fiscal 2024, worth roughly $0.60 of annual EPS if fully regained. BTIG raised its target to $142 from $130 on 5 November 2026, per Benzinga.
  • Net leverage was about 2.5 times earnings before interest, tax, depreciation and amortization.
  • PerQseal Elite is a later second driver. The Food and Drug Administration approved the vascular closure device, the company said on 19 October 2026. Simon put the large-bore closure opportunity at about $300 million globally on the 5 November 2026 call, with about two-thirds in the US.

Bear case

  • CSL's value remains undisclosed. Management gave no CSL revenue figure on 5 November 2026, and Chief Financial Officer James D'Arecca called the contribution "more of a fiscal 28 and beyond" story. Investors must rely on broker estimates such as BTIG's until results show more.
  • The margin promise was cut. Fiscal 2027 adjusted operating margin expansion is now 0 to 0.5 percentage point, down from 0.5 to 1.0 point. D'Arecca attributed the cut to investment ahead of plasma share gains, about 60% of it to performance pay and about 40% to production and oil-related costs.
  • A refund flattered gross margin. Adjusted gross margin rose 1.4 points to 61.9%, including a benefit of roughly 2 points from tariff refunds and a 0.6-point currency headwind. The CFO said it was essentially flat without those items, and adjusted operating margin still fell 0.4 point to 26.3%.
  • The second half must do more. First-half adjusted EPS rose 6% to $2.49, against full-year guidance for growth comparable to the 8–11% reported revenue range. First-half adjusted operating margin fell 0.5 point, and management said expansion is weighted to the fiscal fourth quarter.
  • A new spending cycle is starting. D'Arecca said on 5 November 2026 that manufacturing lines, warehousing and customer device placements "will ignite a new CapEx cycle" lasting roughly two years. He gave no dollar figure.
  • The CSL contract carries no commitment. The agreement is non-exclusive with no minimum purchases, according to the company's August 2026 disclosure.
  • The closure-device launch will be slow. Management described a cautious, stepwise PerQseal Elite launch and expects no material fiscal 2027 revenue. Interventional Technologies grew 3.2% organically to $60.5 million in the second quarter.

Price setup

The shares closed at $124.11 on 5 November 2026 on adjusted daily closes, 2.6% below the 52-week high of $127.42 and up 43.3% over three months. That close is above the $119.65 close of 30 October 2026 and the $122.06 closing high recorded as of that date. The 14-day relative strength index, a momentum gauge, stood at 63.8.

The narrative is maturing: CSL has been widely covered since 8 October 2026, and the 5 November 2026 report moved the debate from whether the business returns to when it reaches earnings. The crowding evidence is the size of the three-month gain and a close above Citi's $123 target from 8 October 2026 and the $110.00 average target MarketBeat showed on 27 October 2026, before the report.

The reference levels are the $127.42 high, the $119.65 close before the report, the convertible notes' conversion price of about $117.12, and $103, where nearly all the gain after CSL's 8 October 2026 statement would be gone. The company bought back no shares in the first six months of fiscal 2027, per its release, against $75.0 million a year earlier.

Catalysts, next 30 days

  • ~4 February 2027, est.: fiscal third-quarter report. This falls beyond the 30-day window but is the next event the case turns on. It shows the pace of CSL conversions, margin progress and whether later conversions enter guidance.
  • ~6 May 2027, est.: fiscal fourth-quarter report and fiscal 2028 guidance. This is the first annual guide covering most of the CSL conversion.

No other company-scheduled event was found for the next 30 days.

Elapsed catalysts

  • ~6 November 2026, est.: second-quarter 10-Q filing. It should show the convertible-note disclosure with the shares above the conversion price. Diluted weighted average shares were 46,463 thousand in the quarter, per the release. (passed 1d ago)

What would change the view

The case breaks if CSL narrows the rollout, moves completion past the end of calendar 2027, or if Haemonetics lowers its 6–9% organic growth range at any report before fiscal 2028. It also breaks if the fiscal third-quarter report drops the 0 to 0.5 point margin-expansion guide, because that would show CSL costs arriving faster than the earnings they support.

The view that guidance leaves room for upside is wrong if the 4 February 2027 (est.) report shows no increase from further fiscal fourth-quarter conversions. The view that second-half earnings accelerate is wrong if full-year adjusted EPS guidance falls below the 8–11% reported revenue range.

On price, a weekly close below $103 ends the thesis, because it would give back nearly all of the gain that followed CSL's 8 October 2026 statement.

What it trades with

The shares have moved on company news more than on the market: they reached a 52-week high on 8 October 2026, a session when US stocks fell, Benzinga reported. The main shared exposures are plasma collection volumes, which management said grew by a mid-to-high single-digit percentage in the US and by a double-digit percentage outside it, and trade policy. Tariffs affect the company directly: refunds lifted second-quarter gross margin by roughly 2 points. Oil-linked freight and materials costs also contributed to the fiscal 2027 margin cut, according to the CFO.

Notes

  • Fiscal year ends late March. FY2027 contains a 53rd week worth about 2 points of reported revenue growth, so reported and organic figures diverge all year.
  • The CSL Plasma agreement is non-exclusive with no minimum purchases. Management does not break out CSL revenue, citing confidentiality and competitive reasons.
  • FY2027 guidance set 5 November 2026 includes CSL centers converted or formally notified through 31 December, excludes later conversions, and assumes no material PerQseal Elite revenue.
  • Since Q1 FY2027 the company reports two segments, Apheresis and MedSurg. Pre-2026 segment history is not directly comparable.
  • $700M of 2.5% convertible notes due 2029 remain outstanding at a ~$117.12 conversion price; long-term debt was $1,114.1M at 26 September 2026.
  • $325.0M of share repurchase authorization remains through April 2028; the company repurchased no shares in the first six months of FY2027.

Sources

Related · shared themes

See also · stocks to watch